Search research articles
Contact Us
Filters
Showing results (1-10 of 32) with videos related to
Page
of 4
Sort By:
Pharmacoeconomics
|
July 31, 2009
Converting the SF-12 into the EQ-5D: an empirical comparison of methodologies
Ling-Hsiang Chuang, Paul Kind
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
July 31, 2010
The effect of health state selection on the valuation of EQ-5D
Ling-Hsiang Chuang, Paul Kind
British Medical Bulletin
|
January 3, 2012
Mapping for economic evaluation
Ling-Hsiang Chuang, Sarah J Whitehead
Medical Care
|
January 27, 2009
Estimating Domestic Values for EQ-5D Health States Using Survey Data From External Sources
Ling-Hsiang Chuang, Victor Zarate, Paul Kind
BMC Public Health
|
October 1, 2025
Self-reported health status in the general population over 2 decades: variation in EQ-5D-3L in Health Survey for England
Ling-Hsiang Chuang, Ranjeeta Thomas, Paul Kind
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
March 8, 2013
Comparative responsiveness and minimal change of the Knee Quality of Life 26-item (KQoL-26) questionnaire
Ling-Hsiang Chuang, Andrew Garratt, Stephen Brealey
Journal of Medical Economics
|
December 20, 2021
Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China
Jia Liu, Lei Zheng, Ling-Hsiang Chuang
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2008
Hispanic valuation of the EQ-5D health states: a social value set for Latin Americans
Victor Zarate, Paul Kind, Ling-Hsiang Chuang
BMC Medical Research Methodology
|
September 12, 2014
Network meta-analysis of (individual patient) time to event data alongside (aggregate) count data
Pedro Saramago, Ling-Hsiang Chuang, Marta O Soares
Health Economics Review
|
June 6, 2024
Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
Shitong Xie, Yanan Sheng, Ling-Hsiang Chuang, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 32) with videos related to
Sort By:
Page
of 4
Pharmacoeconomics
|
July 31, 2009
Converting the SF-12 into the EQ-5D: an empirical comparison of methodologies
Ling-Hsiang Chuang, Paul Kind
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
July 31, 2010
The effect of health state selection on the valuation of EQ-5D
Ling-Hsiang Chuang, Paul Kind
British Medical Bulletin
|
January 3, 2012
Mapping for economic evaluation
Ling-Hsiang Chuang, Sarah J Whitehead
Medical Care
|
January 27, 2009
Estimating Domestic Values for EQ-5D Health States Using Survey Data From External Sources
Ling-Hsiang Chuang, Victor Zarate, Paul Kind
BMC Public Health
|
October 1, 2025
Self-reported health status in the general population over 2 decades: variation in EQ-5D-3L in Health Survey for England
Ling-Hsiang Chuang, Ranjeeta Thomas, Paul Kind
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
March 8, 2013
Comparative responsiveness and minimal change of the Knee Quality of Life 26-item (KQoL-26) questionnaire
Ling-Hsiang Chuang, Andrew Garratt, Stephen Brealey
Journal of Medical Economics
|
December 20, 2021
Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China
Jia Liu, Lei Zheng, Ling-Hsiang Chuang
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2008
Hispanic valuation of the EQ-5D health states: a social value set for Latin Americans
Victor Zarate, Paul Kind, Ling-Hsiang Chuang
BMC Medical Research Methodology
|
September 12, 2014
Network meta-analysis of (individual patient) time to event data alongside (aggregate) count data
Pedro Saramago, Ling-Hsiang Chuang, Marta O Soares
Health Economics Review
|
June 6, 2024
Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
Shitong Xie, Yanan Sheng, Ling-Hsiang Chuang, et al.
Page
of 4